Department of Juvenile Justice Sample Clauses

Department of Juvenile Justice. The Department of Juvenile Justice (DJJ) twelve- 14 month (255- day) calendar will be jointly developed by the DJJ Administrators and 15 Teachers to ensure the required 240-day instructional calendar and the recommendation 16 shall be forwarded to the TALC Labor/Management Committee.
Sample 1Sample 2Sample 3See All (15)
AutoNDA by SimpleDocs
Department of Juvenile Justice. Full time twelve (12) month employees in the TALC 5 vacation requests between April 1 and June 30 of each year for vacation leave that will 6 occur from July 1 through June 30 of the following year. Requests for vacation will be 7 granted based on seniority; however, requests received after June 30 will be considered on 8 a first-come first-served basis.
Sample 1Sample 2See All (4)
Department of Juvenile Justice. XXX, as a participant in the Piedmont JJSAMHP, agrees to: (1) Utilize the GAIN SS for all youth during the intake process. (2) Make direct referrals to the JJSAMHP Providers based on the results of the GAIN SS where clinically indicated by a score of three or more on the Global Assessment of Individual Needs Short Screener (“GAIN SS”). (3) Capture the following data points and report such information to the Piedmont JJSAMHP on a monthly basis, due no later than the 5th day of each month: a. Number of youth on diversion plans; b. Number of youth adjudicated (undisciplined or delinquent); c. Number of youth assessed using the GAIN SS; d. Number of youth assessed using the GAIN-I or GAIN-I Lite; and e. Number of youth referred for involvement with the JJSAMHP. (4) Obtain a signed release of information using the form of release provided by Cardinal Innovations authorizing Cardinal Innovations to disclose or exchange Protected Health Information, as that term is defined by the Health Insurance Portability and Accountability Act of 1996, for any youth referred for JJSAMHP Services; and
Sample 1
Department of Juvenile Justice 
Sample 1

Related to Department of Juvenile Justice

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!